BSI-721

N/A

Report date: 2025/07/08 14:51:49

Base Information

Drug NameBSI-721

Drug Alias NameBSI-721

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payload +[4]

Mechanisms of ActionAnti-Cadherin-17Tubulin polymerisation inhibitors

TargetsCadherin-17Tubulin

Therapy Area/IndicationsGastrointestinal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesBiosion Inc

China Registration ClassN/A

Develop Information

Active CompaniesBiosion Inc

Inactive CompaniesN/A

Active IndicationsGastrointestinal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A